

ForPatients

by Roche

COVID-19 Pneumonia

A study to find out if a new medicine (either astegolimab or efmarodocokin alfa) was safe and effective in patients with severe COVID-19 pneumonia

A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia

Trial Status
Completed

Trial Runs In
4 Countries

Trial Identifier
NCT04386616 GA42469

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase II, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of MSTT1041A (astegolimab) compared with placebo and of UTTR1147A compared with placebo, in combination with standard of care (SOC), in patients hospitalized with severe coronavirus disease 2019 (COVID-19) pneumonia.

Genentech, Inc.
Sponsor

Phase 2
Phase

NCT04386616 GA42469
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No

This clinical trial was done to study two new medicines called, “astegolimab” and “efmarodocokin alfa”, for the treatment of patients with severe COVID-19 pneumonia. This study was done to find out if either medicine was effective and safe for treating patients with severe COVID-19 pneumonia in comparison to placebo treatments. There were 396 patients who took part in this study at 54 study centers in 4 countries.